Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00020410 · ClinicalTrials.gov registry record · Phase 1
Radiolabeled Monoclonal Antibody Followed by Peripheral Stem Cell Transplantation in Treating Patients With Relapsed or Metastatic Breast Cancer
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
NCT00020410: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00020410 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00020410, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Peripheral stem cell transplantation may allow the doctor to give higher doses of monoclonal antibody therapy and kill more cancer cells. PURPOSE: Phase I trial to study the effectiveness of radiolabeled monoclonal antibody followed by peripheral stem cell transplantation in treating patients who have relapsed or metastatic breast cancer.
Interventions
- PROCEDURE peripheral blood stem cell transplantation
- BIOLOGICAL filgrastim
- RADIATION yttrium Y 90 monoclonal antibody B3
Trial Details
| Field | Value |
|---|---|
| Start Date | 2001-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00020410
The ClinicalTrials.gov registry entry for NCT00020410 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which peripheral blood stem cell transplantation is the first listed.
NCT00020410 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00020410 about?
NCT00020410 is a clinical study titled "Radiolabeled Monoclonal Antibody Followed by Peripheral Stem Cell Transplantation in Treating Patients With Relapsed or Metastatic Breast Cancer". RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Peripheral stem cell transplantation may allow the doctor to give higher doses of monoclonal antibody therapy and kill more cancer cells...
What is the current status of trial NCT00020410?
This trial is currently completed. It is a Phase 1 study. The study started on 2001-02.
What interventions are being tested in trial NCT00020410?
The interventions under investigation include: peripheral blood stem cell transplantation (PROCEDURE), filgrastim (BIOLOGICAL), yttrium Y 90 monoclonal antibody B3 (RADIATION).
Who is sponsoring clinical trial NCT00020410?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.